Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? (Q36736174)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Szczepański T

series ordinal

1

1 reference

16 August 2017

15 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

622-626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404603

25 December 2019

exact match

0 references

cites work

Minimal residual disease in leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Determination of minimal residual disease in leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Flow-cytometric immunophenotyping of normal and malignant lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

The MLL recombinome of acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of secon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404603

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404603

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17301806%20AND%20SRC:MED&resulttype=core&format=json

release_zn22svkq3be75mcanygkombgn4

25 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zn22svkq3be75mcanygkombgn4

24 November 2022

mapped directly with Wikidata item

1 reference